IP Verse

Therapeutic Use Of Bone Morphogenetic Proteins - EP3166628

The patent EP3166628 was granted to Cambridge Enterprise on Jul 26, 2023. The application was originally filed on Jul 9, 2015 under application number EP15739658A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3166628

CAMBRIDGE ENTERPRISE
Application Number
EP15739658A
Filing Date
Jul 9, 2015
Status
Patent Maintained As Amended
Jun 23, 2023
Grant Date
Jul 26, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLESep 30, 2020CARPMAELS & RANSFORDADMISSIBLE

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS2006024783
INTERNATIONAL-SEARCH-REPORTWO2008151078
OPPOSITIONEP1571159

Non-Patent Literature (NPL) Citations (8) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
OPPOSITION- KANG et al., "Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinantadenovirus-mediated gene delivery", Gene Therapy, (20040000), vol. 11, pages 1312 - 1320
OPPOSITION- KANG et al., "Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinantadenovirus-mediated gene delivery", Gene Therapy, (20040000), vol. 11, pages 1312 - 1320, XP055739755
OPPOSITION- LONG et al., "Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension", Nature Medicine, (20150000), vol. 21, pages 777 - 785
OPPOSITION- MORELL et al., "Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension", Pulmonary Circulation, (20130000), vol. 3, pages 226 - 244
OPPOSITION- SALMON et al., "Molecular basis of ALKI-mediated signallingby BMP9/BMP10 and their prodomain-boundforms", Nature Communications, (20200000), vol. 11, page 1621
OPPOSITION- SALMON et al., "Molecular basis of ALKI-mediated signallingby BMP9/BMP10 and their prodomain-boundforms", Nature Communications, (20200000), vol. 11, page 1621, XP055739753
OPPOSITION- LONG et al., "Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension", Nature Medicine, (20150000), vol. 21, pages 777 - 785, XP055435858
OPPOSITION- MORELL et al., "Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension", Pulmonary Circulation, (20130000), vol. 3, pages 226 - 244, XP055739764

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents